A5003417891- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
- PI3K/AKT/mTOR signaling in cancer
- BRCA gene mutations in cancer
- PARP inhibition in cancer therapy
- Lung Cancer Treatments and Mutations
- Click Chemistry and Applications
- Optical Imaging and Spectroscopy Techniques
- Monoclonal and Polyclonal Antibodies Research
- Photoacoustic and Ultrasonic Imaging
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- DNA Repair Mechanisms
- Colorectal Cancer Treatments and Studies
- Synthesis and biological activity
- Estrogen and related hormone effects
- Breast Lesions and Carcinomas
- Radiopharmaceutical Chemistry and Applications
- Genetic factors in colorectal cancer
- Cancer-related Molecular Pathways
- Chronic Lymphocytic Leukemia Research
- Spectroscopy Techniques in Biomedical and Chemical Research
Massachusetts General Hospital
2016-2025
Harvard University
2016-2025
Target (United States)
2017-2023
Dana-Farber Cancer Institute
2004-2021
Hadassah Medical Center
2021
National Comprehensive Cancer Network
2020
Fred and Pamela Buffett Cancer Center
2020
AbbVie (United States)
2019
Myriad (Germany)
2019
Roche (Switzerland)
2019
Epithelial-mesenchymal transition (EMT) of adherent epithelial cells to a migratory mesenchymal state has been implicated in tumor metastasis preclinical models. To investigate its role human cancer, we characterized EMT circulating (CTCs) from breast cancer patients. Rare primary simultaneously expressed and markers, but were highly enriched CTCs. Serial CTC monitoring 11 patients suggested an association CTCs with disease progression. In index patient, reversible shifts between these cell...
Ductal carcinoma in situ (DCIS) of the breast represents a heterogeneous group neoplastic lesions ducts. The goal for management DCIS is to prevent development invasive cancer. This manuscript focuses on NCCN Guidelines Panel recommendations workup, primary treatment, risk reduction strategies, and surveillance specific DCIS.
Several new systemic therapy options have become available for patients with metastatic breast cancer, which led to improvements in survival. In addition patient and clinical factors, the treatment selection primarily depends on tumor biology (hormone-receptor status HER2-status). The NCCN Guidelines specific workup of recurrent/stage IV cancer are discussed this article.
BRCA1/2-mutated and some sporadic triple-negative breast cancers (TNBC) have DNA repair defects are sensitive to DNA-damaging therapeutics. Recently, three independent DNA-based measures of genomic instability were developed on the basis loss heterozygosity (LOH), telomeric allelic imbalance (TAI), large-scale state transitions (LST).We assessed a combined homologous recombination deficiency (HRD) score, an unweighted sum LOH, TAI, LST scores, in neoadjuvant TNBC trials platinum-containing...
The therapeutic options for patients with noninvasive or invasive breast cancer are complex and varied. These NCCN Clinical Practice Guidelines Breast Cancer include recommendations clinical management of carcinoma in situ, cancer, Paget disease, phyllodes tumor, inflammatory during pregnancy. content featured this issue focuses on the overall ductal situ workup locoregional early stage cancer. For full version Cancer, visit NCCN.org .
We provide evidence that a class of integrins combines with the adaptor Shc and thereby Grb2. Coimmunoprecipitation mutagenesis experiments indicate recruitment is specified by extracellular or transmembrane domain integrin α subunit suggest this process mediated caveolin. Mutagenesis dominant-negative inhibition studies reveal necessary sufficient for activation MAP kinase pathway in response to ligation. Mitogens Shc-activating cooperate promote transcription from Fos serum element transit...
Standard chemotherapy is associated with low response rates and short progression-free survival among patients pretreated metastatic triple-negative breast cancer. Sacituzumab govitecan-hziy an antibody-drug conjugate that combines a humanized monoclonal antibody, which targets the human trophoblast cell-surface antigen 2 (Trop-2), SN-38, conjugated to antibody by cleavable linker. enables delivery of high concentrations SN-38 tumors.
Patients with hormone receptor-negative breast cancer generally do not benefit from endocrine-targeted therapies. However, a subset androgen receptor (AR) expression is predicted to respond antiandrogen This phase II study explored bicalutamide in AR-positive, estrogen (ER), and progesterone (PgR)-negative metastatic cancer.Tumors patients ER/PgR-negative advanced were tested centrally for AR [immunohistochemistry (IHC) > 10% nuclear staining considered positive]. If either the primary or...
Abstract Activation of the phosphoinositide 3-kinase (PI3K) pathway has been implicated in pathogenesis a variety cancers. Recently, mutations gene encoding p110α catalytic subunit PI3K (PIK3CA) have identified several human The primarily result single amino acid substitutions, with >85% either exon 9 or 20. Multiple studies shown that these are observed 18% to 40% breast However, phenotypic effects PIK3CA not examined epithelial cells. Herein, we examine activity two most common...
These NCCN Guidelines Insights highlight the important updates/changes to surgical axillary staging, radiation therapy, and systemic therapy recommendations for hormone receptor-positive disease in 1.2017 version of Breast Cancer. This report summarizes these updates discusses rationale behind them. Updates on new drug approvals, not available at press time, can be found most recent guidelines NCCN.org.
Pleckstrin homology (PH) domains are small protein modules involved in recruitment of signaling molecules to cellular membranes, some cases by binding specific phosphoinositides. We describe use a convenient "dot-blot" approach screen 10 different PH for those that recognize particular Each domain bound phosphoinositides the assay, but only two (from phospholipase C-δ<sub>1</sub>and Grp1) showed clear specificity single species. Using soluble inositol phosphates, we show Grp1 (originally...
The identification of patients with metastatic triple-negative breast cancer (mTNBC) who are expected to benefit from platinum-based chemotherapy is interest. We conducted a single-arm phase II clinical trial single-agent platinum for mTNBC biomarker correlates.Patients received first- or second-line cisplatin (75 mg/m(2)) carboplatin (area under the concentration-time curve 6) by physician's choice once every 3 weeks. Coprimary end points were objective response rate (RR) and prediction...
Abstract Targeted cancer therapy requires the rapid and accurate identification of genetic abnormalities predictive therapeutic response. We sought to develop a high‐throughput genotyping platform that would allow prospective patient selection best available therapies, could readily inexpensively be adopted by most clinical laboratories. developed highly sensitive multiplexed assay performs very well with nucleic acid derived from formalin fixation paraffin embedding (FFPE) tissue, tests for...
Abstract The COVID-19 pandemic presents clinicians a unique set of challenges in managing breast cancer (BC) patients. As hospital resources and staff become more limited during the pandemic, it becomes critically important to define which BC patients require urgent care can wait for treatment until is over. In this Special Communication, we use expert opinion representatives from multiple organizations categorize into priority levels (A, B, C) urgency across all specialties. Additionally,...
Purpose Trop-2, expressed in most triple-negative breast cancers (TNBCs), may be a potential target for antibody-drug conjugates. Sacituzumab govitecan, an conjugate, targets Trop-2 the selective delivery of SN-38, active metabolite irinotecan. Patients and Methods We evaluated sacituzumab govitecan single-arm, multicenter trial patients with relapsed/refractory metastatic TNBC who received 10 mg/kg starting dose on days 1 8 21-day repeated cycles. The primary end points were safety...
Breast cancer is the most common malignancy in women United States and second only to lung as a cause of death. The overall management breast includes treatment local disease with surgery, radiation therapy, or both, systemic cytotoxic chemotherapy, endocrine biologic combinations these. This article outlines NCCN Guidelines specific that locoregional (restricted one region body), discusses clinical stage I, II, IIIA (T3N1M0) tumors. For on adjuvant therapy after II for other stages cancer,...
The NCCN Guidelines for Breast Cancer include up-to-date guidelines clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory male and cancer during pregnancy. These are developed by a multidisciplinary panel representatives from Member Institutions cancer–focused expertise the fields medical oncology, surgical radiation pathology, reconstructive surgery, patient advocacy. Insights focus on most recent updates to...
Significance Emerging evidence indicates patients who benefit from antiangiogenic therapies have improved vessel function. To determine how bevacizumab modulates morphology to improve function we conducted a phase II trial of preoperative followed by combined with chemotherapy in HER2-negative breast cancer patients. Our results suggest that the clinical response may occur through an increase extent vascular normalization primarily high baseline tumor microvessel density. If validated, these...
African American women are more likely to die as a result of breast cancer than white women. The influence somatic genomic profiles on this racial disparity is unclear. We aimed compare the distribution tumor characteristics and recurrence.We assessed with stage I III diagnosed from 1988 2013 primary tumors submitted Cancer Genome Atlas 2010 2014. used Cox proportional hazards models evaluate association race genetic traits investigated exome sequencing gene expression data in 663 711 105...